Factors Associated with Health-Related Quality of Life in Women with Breast Cancer in the Middle East: A Systematic Review.

Breast Cancer Health-related quality of life Middle East Systematic review Women

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
16 Mar 2020
Historique:
received: 03 02 2020
revised: 09 03 2020
accepted: 09 03 2020
entrez: 20 3 2020
pubmed: 20 3 2020
medline: 20 3 2020
Statut: epublish

Résumé

The aim of the present systematic review was to identify the factors that potentially influence health-related quality of life (HRQoL) in women with breast cancer (BC) in the Middle East. A systematic search of the PubMed, Ovid Medline, Cochrane, Embase, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Scopus, and Ebscohost databases was conducted to identify all relevant articles published in peer-reviewed journals up to April 2018. The keywords were "Health related quality of life", "Breast Cancer", and "Middle East countries". The Newcastle-Ottawa (NOS) scale was used to evaluate the methodological quality of the included studies. Due to the methodological heterogeneity of the identified studies, no statistical pooling of the individual effect estimates was carried out; instead, the results were summarized descriptively. A total of 5668 articles were screened and 33 studies were retained. The vast majority of these studies were cross-sectional and only two were longitudinal prospective studies. Concerning the methodological quality, only 39% were of high quality. Our comprehensive literature review identified several modifiable and non-modifiable risk factors associated with HRQoL, including sociodemographic, clinical, and treatment-related factors as well as behavioral and psychosocial factors. This study has many implications for clinical practice and may provide a framework for establishing policy interventions to improve HRQoL among women with BC. Healthcare systems in the Middle East are encouraged to develop interventional programs targeting modifiable factors, particularly socio-demographic, behavioral, and psychosocial factors.

Identifiants

pubmed: 32187972
pii: cancers12030696
doi: 10.3390/cancers12030696
pmc: PMC7140018
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Références

Breast Cancer Res. 2012 Mar 27;14(2):R55
pubmed: 22452927
Oncol Nurs Forum. 2017 Jan 1;44(1):127-136
pubmed: 27991612
Public Health. 2016 Jul;136:117-25
pubmed: 27085319
Iran J Nurs Midwifery Res. 2013 Mar;18(2):105-11
pubmed: 23983738
J Relig Health. 2017 Dec;56(6):2096-2108
pubmed: 28168582
Saudi Pharm J. 2018 Mar;26(3):416-421
pubmed: 29556133
Asian Pac J Cancer Prev. 2012;13(3):941-4
pubmed: 22631676
Health Qual Life Outcomes. 2015 Mar 28;13:40
pubmed: 25889384
Acta Med Iran. 2017 Jan;55(1):35-41
pubmed: 28188941
SSM Popul Health. 2016 Mar 05;2:155-163
pubmed: 29349136
Eur J Oncol Nurs. 2008 Dec;12(5):449-56
pubmed: 18842460
BMC Cancer. 2013 Apr 28;13:212
pubmed: 23622020
J Clin Oncol. 1998 May;16(5):1689-96
pubmed: 9586880
Psychooncology. 2014 Sep;23(9):1014-20
pubmed: 24700668
Breast Cancer Res Treat. 2012 Feb;131(3):1061-6
pubmed: 22080245
Indian J Cancer. 2008 Jul-Sep;45(3):107-11
pubmed: 19018114
Support Care Cancer. 2013 May;21(5):1219-25
pubmed: 23138932
J Cancer Epidemiol. 2013;2013:916394
pubmed: 24282410
Asian Pac J Cancer Prev. ;18(8):2089-2092
pubmed: 28843227
J BUON. 2016 May-Jun;21(3):549-55
pubmed: 27569071
Eur J Oncol Nurs. 2012 Dec;16(5):491-7
pubmed: 22257429
J Clin Oncol. 1994 Mar;12(3):608-16
pubmed: 8120561
Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
Breast Cancer (Dove Med Press). 2017 Feb 09;9:51-58
pubmed: 28223845
Psychol Health Med. 2008 Oct;13(5):559-73
pubmed: 18942009
J Nurs Scholarsh. 2004;36(3):207-13
pubmed: 15495488
Asian Pac J Cancer Prev. 2013;14(12):7749-55
pubmed: 24460363
Qual Life Res. 2005 Oct;14(8):1813-23
pubmed: 16155769
Eur J Cancer Care (Engl). 2014 Sep;23(5):675-84
pubmed: 24450945
J Pain. 2006 Sep;7(9):626-34
pubmed: 16942948
Breast Cancer Res Treat. 2000 Jul;62(2):141-50
pubmed: 11016752
Jpn J Clin Oncol. 2012 Dec;42(12):1168-74
pubmed: 23081984
Asia Pac J Oncol Nurs. 2018 Apr-Jun;5(2):217-222
pubmed: 29607383
East Mediterr Health J. 2017 Feb 01;22(11):786-793
pubmed: 28177108
PLoS One. 2016 Apr 15;11(4):e0153714
pubmed: 27082440
Ann Intern Med. 2015 Jun 2;162(11):777-84
pubmed: 26030634
Psychol Health Med. 2013;18(4):412-9
pubmed: 23116204
Breast Cancer Res Treat. 2019 Apr;174(3):585-596
pubmed: 30632022
Psychooncology. 2007 Apr;16(4):329-41
pubmed: 16888704
Iran J Nurs Midwifery Res. 2015 Mar-Apr;20(2):287-91
pubmed: 25878710
Oncol Rev. 2012 Jan 30;6(1):e2
pubmed: 25992204
Asian Pac J Cancer Prev. ;18(10):2809-2816
pubmed: 29072421
West Indian Med J. 2007 Jun;56(3):253-7
pubmed: 18072408
Psychother Psychosom. 2010;79(1):31-8
pubmed: 19887889
Psychooncology. 2009 Aug;18(8):831-40
pubmed: 19034922
BMC Cancer. 2009 Jul 08;9:222
pubmed: 19586536
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Asian Pac J Cancer Prev. 2016;17(2):643-6
pubmed: 26925657
Asian Pac J Cancer Prev. 2015;16(17):7721-5
pubmed: 26625787
Psychooncology. 2016 Jul;25(7):873-6
pubmed: 26315583
Breast Cancer Res Treat. 2010 Sep;123(2):507-24
pubmed: 20140494
Am J Prev Med. 2016 Feb;50(2):249-54
pubmed: 26775903
Asian Pac J Cancer Prev. 2011;12(9):2335-41
pubmed: 22296380
CA Cancer J Clin. 2002 Jul-Aug;52(4):229-46
pubmed: 12139234

Auteurs

Rana El Haidari (R)

Environments and Health doctoral school, University of Bourgogne Franche-Comté, 25000 Besançon, France.
INSERM (French Institut of Health and Medical Research), EFS BFC (Etablissement français du sang Bourgogne franhce-comté), UMR1098 (Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique), University of Bourgogne Franche-Comté, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France.

Linda Abou Abbas (LA)

Neuroscience research center, Faculty of medical sciences, Lebanese university, 1001 Beirut, Lebanon.

Virginie Nerich (V)

INSERM (French Institut of Health and Medical Research), EFS BFC (Etablissement français du sang Bourgogne franhce-comté), UMR1098 (Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique), University of Bourgogne Franche-Comté, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France.
Department of Pharmacy, University Hospital of Besançon, 25030 Besançon, France.

Amélie Anota (A)

INSERM (French Institut of Health and Medical Research), EFS BFC (Etablissement français du sang Bourgogne franhce-comté), UMR1098 (Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique), University of Bourgogne Franche-Comté, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France.
Methodology and Quality of Life in Oncology Unit, University Hospital of Besançon, 25000 Besançon, France.
French National Platform Quality of Life and Cancer, 250000 Besançon, France.

Classifications MeSH